Economic analysis of pertussis illness in the Dutch population: Implications for current and future vaccination strategies

Vaccine

Volumn 27, Issue 13, 2009, Pages 1932-1937

  de Greeff, Sabine C ^a   Lugnér, Anna K ^a   van den Heuvel, Danielle M ^a   Mooi, Frits R ^a   de Melker, Hester E ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Cost of illness; Pertussis; Vaccination

Indexed keywords

PERTUSSIS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DRUG COST; HUMAN; INFANT; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MONEY; NETHERLANDS; PERTUSSIS; PRIORITY JOURNAL; VACCINATION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; HEALTH CARE COSTS; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION, SECONDARY; INFANT; MIDDLE AGED; NETHERLANDS; PERTUSSIS VACCINE; RETROSPECTIVE STUDIES; WHOOPING COUGH; YOUNG ADULT;

EID: 61349094029     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.01.106     Document Type: Article

References (46)

1. Celentano L.P., Massari M., Paramatti D., Salmaso S., and Tozzi A.E. Resurgence of pertussis in Europe. Pediatr Infect Dis J 24 9 (2005) 761-765
2. Ntezayabo B., De Serres G., and Duval B. Pertussis resurgence in Canada largely caused by a cohort effect. Pediatr Infect Dis J 22 1 (2003) 22-27
3. Quinn H.E., and McIntyre P.B. Pertussis epidemiology in Australia over the decade 1995-2005-trends by region and age group. Commun Dis Intell 31 2 (2007) 205-215
4. Mooi F.R., van Loo I.H., and King A.J. Adaptation of Bordetella pertussis to vaccination: a cause for its reemergence?. Emerg Infect Dis 7 Suppl. 3 (2001) 526-528
5. Guris D., Strebel P.M., Bardenheier B., Brennan M., Tachdjian R., Finch E., et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis 28 6 (1999) 1230-1237
6. de Greeff S.C., Mooi F.R., Schellekens J.F., and de Melker H.E. Impact of acellular pertussis preschool booster vaccination on disease burden of pertussis in The Netherlands. Pediatr Infect Dis J 27 3 (2008) 218-223
7. Skowronski D.M., De Serres G., MacDonald D., Wu W., Shaw C., Macnabb J., et al. The changing age and seasonal profile of pertussis in Canada. J Infect Dis 185 10 (2002) 1448-1453
8. Yih W.K., Lett S.M., des Vignes F.N., Garrison K.M., Sipe P.L., and Marchant C.D. The increasing incidence of pertussis in Massachusetts adolescents and adults, 1989-1998. J Infect Dis 182 5 (2000) 1409-1416
9. de Melker H.E., Versteegh F.G., Schellekens J.F., Teunis P.F., and Kretzschmar M. The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. J Infect 53 2 (2006) 106-113
10. Bisgard K.M., Pascual F.B., Ehresmann K.R., Miller C.A., Cianfrini C., Jennings C.E., et al. Infant pertussis: who was the source?. Pediatr Infect Dis J 23 11 (2004) 985-989
11. Elliott E., McIntyre P., Ridley G., Morris A., Massie J., McEniery J., et al. National study of infants hospitalized with pertussis in the acellular vaccine era. Pediatr Infect Dis J 23 3 (2004) 246-252
12. Wendelboe A.M., Njamkepo E., Bourillon A., Floret D.D., Gaudelus J., Gerber M., et al. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J 26 4 (2007) 293-299
13. Forsyth K., Tan T., von Konig C.H., Caro J.J., and Plotkin S. Potential strategies to reduce the burden of pertussis. Pediatr Infect Dis J 24 Suppl. 5 (2005) S69-74
14. Purdy K.W., Hay J.W., Botteman M.F., and Ward J.I. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clin Infect Dis 39 1 (2004) 20-28
15. Scuffham P.A., and McIntyre P.B. Pertussis vaccination strategies for neonates-an exploratory cost-effectiveness analysis. Vaccine 22 21-22 (2004) 2953-2964
16. Caro J.J., Getsios D., Payne K., Annemans L., Neumann P.J., and Trindade E. Economic burden of pertussis and the impact of immunization. Pediatr Infect Dis J 24 Suppl. 5 (2005) S48-54
17. Lee G.M., Murphy T.V., Lett S., Cortese M.M., Kretsinger K., Schauer S., et al. Cost effectiveness of pertussis vaccination in adults. Am J Prev Med 32 3 (2007) 186-193
18. Lee G.M., Lebaron C., Murphy T.V., Lett S., Schauer S., and Lieu T.A. Pertussis in adolescents and adults: should we vaccinate?. Pediatrics 115 6 (2005) 1675-1684
19. Iskedjian M., Walker J.H., and Hemels M.E. Economic evaluation of an extended acellular pertussis vaccine programme for adolescents in Ontario, Canada. Vaccine 22 31-32 (2004) 4215-4227
20. O'Brien J.A., and Caro J.J. Hospitalization for pertussis: profiles and case costs by age. BMC Infect Dis 5 (2005) 57
21. Calugar A., Ortega-Sanchez I.R., Tiwari T., Oakes L., Jahre J.A., and Murphy T.V. Nosocomial pertussis: costs of an outbreak and benefits of vaccinating health care workers. Clin Infect Dis 42 7 (2006) 981-988
22. Ward A., Caro J., Bassinet L., Housset B., O'Brien J.A., and Guiso N. Health and economic consequences of an outbreak of pertussis among healthcare workers in a hospital in France. Infect Control Hosp Epidemiol 26 3 (2005) 288-292
23. Lee G.M., Lett S., Schauer S., LeBaron C., Murphy T.V., Rusinak D., et al. Societal costs and morbidity of pertussis in adolescents and adults. Clin Infect Dis 39 11 (2004) 1572-1580
24. Lee L.H., and Pichichero M.E. Costs of illness due to Bordetella pertussis in families. Arch Fam Med 9 10 (2000) 989-996
25. de Melker H.E., Versteegh F.G., Conyn-Van Spaendonck M.A., Elvers L.H., Berbers G.A., van Der Zee A., et al. Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis. J Clin Microbiol 38 2 (2000) 800-806
26. Central Statistics Netherlands. StatLine database available at http://statline.cbs.nl/statweb/.
27. De Greeff SC, Mooi FR, De Melker HE. Sources of infection of pertussis in infants too young to be vaccinated. In: Book of abstracts of the 25th annual meeting of the European Society for Paediatric Infectious Diseases; Porto, Portugal; 2007 [abstract 95].
28. De Serres G., Shadmani R., Duval B., Boulianne N., Dery P., Douville Fradet M., et al. Morbidity of pertussis in adolescents and adults. J Infect Dis 182 1 (2000) 174-179
29. Postels-Multani S., Schmitt H.J., Wirsing von Konig C.H., Bock H.L., and Bogaerts H. Symptoms and complications of pertussis in adults. Infection 23 3 (1995) 139-142
30. Neppelenbroek SN, de Melker HEd, Schellekens JF, Rumke HC, Suijkerbuijk AWM, Conyn-van Spaendonck MAE. Severity of pertussis: paediatric surveillance and notification study in the Netherlands in 1997: National Institute for Public Health and the Environment; 1999. Report No.: 128507006, available at http://www.rivm.nl/bibliotheek/rapporten/128507006.html.
31. Abbink F, Oomen PJ, Zwakhals SLN, de Melker HE, Ambler-Huiskes A. Immunization coverage in the Netherlands as at 1 January 2005: National Institute for Public Health and the Environment; 2006. Report No.: RIVM report 210021005, available at http://www.rivm.nl/bibliotheek/rapporten/210021005.html.
32. Lee G.M., Salomon J.A., LeBaron C.W., and Lieu T.A. Health-state valuations for pertussis: methods for valuing short-term health states. Health Qual Life Outcomes 3 (2005) 17
33. College voor Zorgverzekeringen. Guidelines for pharmacoeconomic research, updated version. Valid from April 1st 2006. Diemen, The Netherlands; 2006.
34. De Melker HE, Hahné SJM, de Boer IM. The National Immunization Programma in The Netherlands: National Institute for Public Health and the Environment; 2005. Report No.: 210021002, available at http://www.rivm.nl/bibliotheek/rapporten/210021002.html.
35. Pichichero M.E., and Treanor J. Economic impact of pertussis. Arch Pediatr Adolesc Med 151 1 (1997) 35-40
36. Edmunds W.J., Brisson M., Melegaro A., and Gay N.J. The potential cost-effectiveness of acellular pertussis booster vaccination in England and Wales. Vaccine 20 9-10 (2002) 1316-1330
37. Niessen W.J., Broer J., and Schellekens J.F. The obligatory notification of pertussis is not effective for the protection of unvaccinated children. Ned Tijdschr Geneeskd 152 2 (2008) 86-90
38. Bults M., Kemmeren J.M., and van der Maas N.A. Adverse events following booster doses of diphtheria-tetanus-inactivated poliovirus and acellular pertussis vaccines for 4-year-old children in The Netherlands. Vaccine 25 29 (2007) 5272-5277
39. Van Rie A., and Hethcote H.W. Adolescent and adult pertussis vaccination: computer simulations of five new strategies. Vaccine 22 23-24 (2004) 3154-3165
40. Lee G.M., Riffelmann M., and Wirsing von Konig C.H. Cost-effectiveness of adult pertussis vaccination in Germany. Vaccine 26 29-30 (2008) 3673-3679
41. Rodriguez-Cobo I., Chen Y.F., Olowokure B., and Litchfield I. Clinical and economic assessment of different general population strategies of pertussis vaccine booster regarding number of doses and age of application for reducing whooping cough disease burden: a systematic review. Vaccine 26 52 (2008) 6768-6776
42. Knuf M., Schmitt H.J., Wolter J., Schuerman L., Jacquet J.M., Kieninger D., et al. Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants. J Pediatr 152 5 (2008) 655-660
43. Siegrist C.A. Blame vaccine interference, not neonatal immunization, for suboptimal responses after neonatal diphtheria, tetanus, and acellular pertussis immunization. J Pediatr 153 3 (2008) 305-307
44. Mooi F.R., and de Greeff S.C. The case for maternal vaccination against pertussis. Lancet Infect Dis 7 9 (2007) 614-624
45. Oostenbrink JB BC, Koopmanschap MA, Rutten FFH. Handleiding voor kostenonderzoek, methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg; 2004.
46. TNO/LUMC. Groei-onderzoek 1997: Bohn Stafleu Van Loghum; 1998.